Literature DB >> 19250671

Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia.

Zhifang Xu1, Min Wang, Lin Wang, Yang Wang, Xin Zhao, Qing Rao, Jianxiang Wang.   

Abstract

The tuberous sclerosis (TSC) genes, TSC1 and TSC2, encode hamartin and tuberin, respectively, and are putative tumor suppressor genes that were originally identified due to their involvement in the inherited autosomal dominant disorder tuberous sclerosis. It has been elucidated that the two proteins form an intracellular heterodimer participating in signaling pathway of the mammalian Target of Rapamycin (mTOR). Recent studies showed that mTOR pathway was frequently activated in blasts from acute myeloid leukemia (AML) patient and associated with proliferation, survival, and drug-resistance of these cells. These phenomena led us to hypothesize that TSC gene might be involved in acute leukemia (AL). In this study, we investigated the TSC1 and TSC2 mRNA expression in 104 newly diagnosed AL patients and 29 healthy controls using real-time quantitative PCR (RQ-PCR) and explored the potential mechanisms of the aberrant expression through methylation-specific PCR (MSP). The results showed that the expression of TSC2 was downregulated in AL patients and the TSC2 promoter was hypermethylated which might be an important mechanism for the downregulation of TSC2 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250671     DOI: 10.1016/j.leukres.2009.01.041

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

Review 1.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

2.  eIF4F suppression in breast cancer affects maintenance and progression.

Authors:  Z Nasr; F Robert; J A Porco; W J Muller; J Pelletier
Journal:  Oncogene       Date:  2012-04-09       Impact factor: 9.867

Review 3.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

4.  Multifaceted roles of PTEN and TSC orchestrate growth and differentiation of Drosophila blood progenitors.

Authors:  Michelle Dragojlovic-Munther; Julian A Martinez-Agosto
Journal:  Development       Date:  2012-09-05       Impact factor: 6.868

Review 5.  The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Authors:  Alberto M Martelli; Camilla Evangelisti; Francesca Chiarini; James A McCubrey
Journal:  Oncotarget       Date:  2010-06

6.  [Effect of TSC2 gene expression downregulation by lentivirus induced RNA interference on U937 cell line and its mechanism].

Authors:  Z F Xu; H X Liu; Y H Tan; X H Chen; F G Ren; Y F Zhang; J M Chang; N Zhang; J J Hu; H W Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

7.  Interstitial chromosomal deletion of the tuberous sclerosis complex 2 locus is a signature for radiation-associated renal tumors in Eker rats.

Authors:  Tatsuya Inoue; Toshiaki Kokubo; Kazuhiro Daino; Hiromi Yanagihara; Fumiko Watanabe; Chizuru Tsuruoka; Yoshiko Amasaki; Takamitsu Morioka; Shino Homma-Takeda; Toshiyuki Kobayashi; Okio Hino; Yoshiya Shimada; Shizuko Kakinuma
Journal:  Cancer Sci       Date:  2020-02-03       Impact factor: 6.716

8.  The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.

Authors:  Peter Tan; Ing Soo Tiong; Shaun Fleming; Giovanna Pomilio; Nik Cummings; Mark Droogleever; Julie McManus; Anthony Schwarer; John Catalano; Sushrut Patil; Sharon Avery; Andrew Spencer; Andrew Wei
Journal:  Oncotarget       Date:  2016-11-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.